P
Phylos
Phylos is dedicated to the discovery and development of novel biopharmaceuticals
About Phylos
Phylos operates as an agricultural genomics company with a sharp focus on the cannabis sector, founded in February 2014 by Mowgli Holmes and Nishan Karassik in Portland, Oregon. Holmes, an evolutionary biologist, identified a significant lack of scientific research in the cannabis industry as it was beginning to expand. This observation prompted the creation of Phylos to apply modern science to cannabis cultivation. Karassik brought entrepreneurial experience to the venture. The company initially gained prominence by developing the Phylos Galaxy, a 3D interactive map visualizing the genetic relationships between thousands of cannabis varieties, created in partnership with the American Museum of Natural History.
The firm's business model is centered on empowering cannabis growers by providing genetically superior products and data. It generates revenue through the sale of its proprietary cannabis seeds to both commercial-scale cultivators and home growers, offering volume pricing for larger clients. Phylos has also established the "Natural Natural" brand to market products containing rare cannabinoids like THCV, which it derives from its specialized plant varieties. A key part of its strategy involves forming innovation partnerships with operators, such as Organigram in Canada, providing them with genetic material and expertise to improve cultivation efficiency and develop new products.
Phylos' core offering is its Production-Ready Seed™, which includes fully feminized, F1 hybrid seed lines. These seeds are designed to produce plants with high uniformity, vigor, and desirable traits like specific cannabinoid and terpene profiles, rivaling the consistency of traditional cloning methods. The benefits for growers include reduced operational costs, elimination of mother rooms, shorter cultivation cycles, and decreased risk of pests and diseases like Hop Latent Viroid (HLVd). The company offers several seed categories, including Elite, Premium, and Autoflower varieties, catering to different grower needs and expertise levels. The development process utilizes marker-assisted selection, allowing Phylos to identify desirable traits at the seedling stage and accelerate breeding cycles.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Lexington, United States
- Open positions
- None listed
- Dealroom signal
- 1.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2001 | $25M | $100M | Lone Pine Capital · Sprout Group · Three Arch Partners | — |
Growth signals
Latest recorded traffic for Phylos is 0 monthly website visits, down 100% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Lone Pine Capital
Sprout Group
Three Arch Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phylos on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phylos’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







